<SEC-DOCUMENT>0001104659-21-136558.txt : 20211110
<SEC-HEADER>0001104659-21-136558.hdr.sgml : 20211110
<ACCEPTANCE-DATETIME>20211110060314
ACCESSION NUMBER:		0001104659-21-136558
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20211110
DATE AS OF CHANGE:		20211110

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cryoport, Inc.
		CENTRAL INDEX KEY:			0001124524
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880313393
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-251354
		FILM NUMBER:		211394236

	BUSINESS ADDRESS:	
		STREET 1:		112 WESTWOOD PLACE, SUITE 350
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
		BUSINESS PHONE:		(949) 232-1900

	MAIL ADDRESS:	
		STREET 1:		112 WESTWOOD PLACE, SUITE 350
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CRYOPORT SYSTEMS LLC
		DATE OF NAME CHANGE:	20010614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CRYOPORT SYSTEMS INC
		DATE OF NAME CHANGE:	20000923

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cryoport, Inc.
		CENTRAL INDEX KEY:			0001124524
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880313393
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		112 WESTWOOD PLACE, SUITE 350
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027
		BUSINESS PHONE:		(949) 232-1900

	MAIL ADDRESS:	
		STREET 1:		112 WESTWOOD PLACE, SUITE 350
		CITY:			BRENTWOOD
		STATE:			TN
		ZIP:			37027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CRYOPORT SYSTEMS LLC
		DATE OF NAME CHANGE:	20010614

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CRYOPORT SYSTEMS INC
		DATE OF NAME CHANGE:	20000923
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>tm2132514d1_fwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Issuer Free Writing Prospectus</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Filed Pursuant to Rule 433</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Registration Statement No. 333-251354</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Relating to the</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Preliminary Prospectus Supplement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Dated November 8, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">(To Prospectus Dated December 15, 2020)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRICING TERM SHEET</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>November 9, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cryoport, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Placement of</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3,072,038 shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The information in this pricing term sheet
supplements Cryoport, Inc.&rsquo;s preliminary prospectus supplement, dated November 8, 2021 (the &ldquo;Preliminary Prospectus Supplement&rdquo;),
relating to a registered direct placement of common stock (the &ldquo;Common Stock Placement&rdquo;), and supersedes the information in
the Preliminary Prospectus Supplement to the extent inconsistent with the information in the Preliminary Prospectus Supplement. Terms
used, but not defined, in this pricing term sheet have the respective meanings set forth in the Preliminary Prospectus Supplement. As
used in this pricing term sheet, &ldquo;we,&rdquo; &ldquo;our&rdquo; and &ldquo;us&rdquo; refer to Cryoport, Inc. and not to its subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; width: 28%; vertical-align: top"><FONT STYLE="font-size: 10pt">Issuer</FONT></TD>
    <TD STYLE="font-size: 10pt; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left; width: 70%"><FONT STYLE="font-size: 10pt">Cryoport, Inc.</FONT></TD></TR><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">Securities Offered</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">3,072,038 shares of common stock, $0.001 par value per share, of Cryoport, Inc. (the &ldquo;Common Stock&rdquo;).</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">Ticker / Exchange for Common Stock</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">CYRX / The Nasdaq Capital Market (&ldquo; Nasdaq&rdquo;).</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">Last Reported Sale Price per Share of Common Stock on Nasdaq on November 9, 2021</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">$81.10.</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">Offering Price per Share of Common Stock</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">$81.10.</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">Trade Date</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">November 10, 2021.</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">Settlement Date</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">November 12, 2021.</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">Concurrent Offering</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">On
November 9, 2021, we announced the pricing of our previously announced private offering of $350,000,000 aggregate principal amount of
0.75% convertible senior notes due 2026 (the &ldquo;Notes&rdquo;). The offering size was increased from the previously announced offering
size of $300,000,000 aggregate principal amount of Notes. The issuance and sale of the Notes are scheduled to settle on November 12, 2021,
subject to customary closing conditions. We granted the initial purchasers of the Concurrent Offering an option to purchase, for settlement
within a period of 13 days from, and including, the date the Notes are first issued, up to an additional $52,500,000 principal amount
of Notes.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top; width: 28%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify; width: 70%">The Notes will accrue interest at a
rate of 0.75% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, beginning on June 1, 2022. The initial
conversion rate of the Notes is 8.5038 shares of Common Stock per $1,000 principal amount of Notes, which represents an initial conversion
price of approximately $117.59 per share of Common Stock. The conversion rate and conversion price will be subject to adjustment upon
the occurrence of certain events.</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">We estimate that the net proceeds to
us from the Concurrent Offering, if it is consummated, will be approximately $339.0 million (or approximately $389.9 million if the initial
purchasers of the Concurrent Offering fully exercise their option to purchase additional Notes), after deducting the initial purchasers&rsquo;
discounts and commissions and our estimated offering expenses.</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">The completion of the Common Stock
Placement is contingent on the completion of the Concurrent Offering, but the completion of the Concurrent Offering is not contingent
on the completion of the Common Stock Placement.</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">The Concurrent Offering is being made
pursuant to a confidential offering memorandum only to qualified institutional buyers (as defined in Rule 144A under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;)) in transactions that are exempt from the registration and prospectus-delivery
requirements of the Securities Act. This pricing term sheet does not constitute an offer to sell, or the solicitation of an offer to buy,
any securities being offered in the Concurrent Offering. See &ldquo;The Concurrent Offering&rdquo; in the Preliminary Prospectus Supplement.</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">Use of Proceeds</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">We
estimate that the net proceeds to us from the Common Stock Placement will be approximately $248.6 million, after deducting our estimated
offering expenses. We intend to use the net proceeds from the Common Stock Placement and a portion of the net proceeds from the Concurrent
Offering to repurchase approximately $100.7 million principal amount of our outstanding 3.00% Convertible Senior Notes due 2025 (the &ldquo;2025
convertible notes&rdquo;) in separate, privately negotiated repurchase transactions with a limited number of holders of our 2025 convertible
notes for an aggregate repurchase price of approximately $351.1 million, which includes accrued and unpaid interest on the repurchased
2025 convertible notes. We intend to use the remainder of the net proceeds from the Concurrent Offering for general corporate purposes.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top; width: 28%">Placement Agents</TD>
    <TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify; width: 70%">Jefferies LLC<BR>
 SVB Leerink LLC</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: left; font-size: 10pt; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                                              <TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-size: 10pt; vertical-align: top">CUSIP / ISIN Numbers for the Common Stock</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: justify">229050307 / US2290503075.</TD></TR>
                                                                                                                                                                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have filed a registration statement (including
a prospectus) and the Preliminary Prospectus Supplement with the SEC for the Common Stock Placement to which this communication relates.
Before you invest, you should read the Preliminary Prospectus Supplement and the prospectus in that registration statement and other documents
we have filed with the SEC for more complete information about us and the Common Stock Placement. You may get these documents free by
visiting EDGAR on the SEC website at www.sec.gov. Alternatively, we will arrange to send you the Preliminary Prospectus Supplement (or,
when available, the final prospectus supplement) and the accompanying prospectus upon request to: Cryoport, Inc. 112 Westwood Place, Suite
350, Brentwood, TN 37027, Attn: Chief Financial Officer or (949) 470-2300.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The information in this pricing term sheet
is not a complete description of the Common Stock or the Common Stock Placement. You should rely only on the information contained or
incorporated by reference in the Preliminary Prospectus Supplement and the accompanying prospectus, as supplemented by this pricing term
sheet, in making an investment decision with respect to the Common Stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR
BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED
AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
